Literature DB >> 32031628

Lymphedema Signs, Symptoms, and Diagnosis in Women Who Are in Minority and Low-Income Groups and Have Survived Breast Cancer.

Ann Marie Flores1, Jason Nelson2, Lee Sowles3, Rebecca G Stephenson4, Kathryn Robinson5, Andrea Cheville6, Antoinette P Sander7, William J Blot8.   

Abstract

BACKGROUND: Breast cancer-related lymphedema (BCRL) is a well-known side effect of cancer and its treatment with wide-ranging prevalence estimates.
OBJECTIVE: This study describes associations between breast cancer-related lymphedema (BCRL) signs, symptoms, and diagnosis for women who were African American, white, or had a low income and survived breast cancer.
DESIGN: This is a cross-sectional, observational study that used a computer-assisted telephone interview.
METHODS: Women who had survived breast cancer were queried on the presence of 5 lymphedema signs and symptoms (edema in the breast, axilla, arm, and/or hand; tissue fibrosis; pitting; hemosiderin staining; heaviness) and whether they had a diagnosis of BCRL. Relationships between signs/symptoms and diagnosis for each group were evaluated with kappa and chi-square statistics.
RESULTS: The study sample included 528 women who had survived breast cancer (266 white and 262 African American), with 514 reporting complete data on household income; 45% of the latter reported an annual household income of ≤$20,000. Women who were African American or had a low income were nearly twice as likely as women who were white to have any of 8 signs/symptoms of BCRL. Regardless of race and income, >50% of women with all BCRL signs and symptoms reported that they were not diagnosed with BCRL. LIMITATIONS: The main limitations of our study are the lack of medical chart data and longitudinal design.
CONCLUSIONS: Women who were African American or had a low income and had survived breast cancer had a greater burden of BCRL signs and symptoms than women who were white. The lack of a strong association between BCRL signs, symptoms, and diagnosis suggests that BCRL may be underdiagnosed. These findings suggest that more rigorous screening and detection of BCRL-especially for women who are African American or have a low income-may be warranted. Cancer rehabilitation programs may be able to fill this gap.
© 2020 American Physical Therapy Association.

Entities:  

Mesh:

Year:  2020        PMID: 32031628      PMCID: PMC7246063          DOI: 10.1093/ptj/pzaa002

Source DB:  PubMed          Journal:  Phys Ther        ISSN: 0031-9023


  58 in total

1.  Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel : Part 1: Definitions, Assessments, Education, and Future Directions.

Authors:  Sarah A McLaughlin; Alicia C Staley; Frank Vicini; Paul Thiruchelvam; Nancy A Hutchison; Jane Mendez; Fiona MacNeill; Stanley G Rockson; Sarah M DeSnyder; Suzanne Klimberg; Michael Alatriste; Francesco Boccardo; Mark L Smith; Sheldon M Feldman
Journal:  Ann Surg Oncol       Date:  2017-08-01       Impact factor: 5.344

2.  Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy.

Authors:  Jane M Armer; Karla V Ballman; Linda McCall; Nathan C Armer; Yuanlu Sun; Tipparat Udmuangpia; Kelly K Hunt; Elizabeth A Mittendorf; David R Byrd; Thomas B Julian; Judy C Boughey
Journal:  Support Care Cancer       Date:  2018-07-06       Impact factor: 3.603

3.  Physical activity, body mass index, and mammographic density in postmenopausal breast cancer survivors.

Authors:  Melinda L Irwin; Erin J Aiello; Anne McTiernan; Leslie Bernstein; Frank D Gilliland; Richard N Baumgartner; Kathy B Baumgartner; Rachel Ballard-Barbash
Journal:  J Clin Oncol       Date:  2007-01-29       Impact factor: 44.544

4.  Adverse breast cancer treatment effects: the economic case for making rehabilitative programs standard of care.

Authors:  Kathryn H Schmitz; Tracey DiSipio; Louisa G Gordon; Sandra C Hayes
Journal:  Support Care Cancer       Date:  2014-12-05       Impact factor: 3.603

5.  The Diagnosis and Treatment of Peripheral Lymphedema: 2016 Consensus Document of the International Society of Lymphology.

Authors: 
Journal:  Lymphology       Date:  2016-12       Impact factor: 1.286

6.  Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?

Authors:  Michelle C Specht; Cynthia L Miller; Tara A Russell; Nora Horick; Melissa N Skolny; Jean A O'Toole; Lauren S Jammallo; Andrzej Niemierko; Betro T Sadek; Mina N Shenouda; Dianne M Finkelstein; Barbara L Smith; Alphonse G Taghian
Journal:  Breast Cancer Res Treat       Date:  2013-08-04       Impact factor: 4.872

7.  Cording following treatment for breast cancer.

Authors:  Jean O'Toole; Cynthia L Miller; Michelle C Specht; Melissa N Skolny; Lauren S Jammallo; Nora Horick; Krista Elliott; Andrzej Niemierko; Alphonse G Taghian
Journal:  Breast Cancer Res Treat       Date:  2013-06-29       Impact factor: 4.872

8.  Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors.

Authors:  Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

9.  Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up.

Authors:  Ana Carolina Padula Ribeiro Pereira; Rosalina Jorge Koifman; Anke Bergmann
Journal:  Breast       Date:  2017-10-06       Impact factor: 4.380

10.  Physical impairments and physical therapy services for minority and low-income breast cancer survivors.

Authors:  Ann Marie Flores; Jason Nelson; Lee Sowles; Karen Bienenstock; William J Blot
Journal:  Springerplus       Date:  2016-08-02
View more
  1 in total

1.  Neighborhood socioeconomic status and low-value breast cancer care.

Authors:  J C Chen; Yaming Li; James L Fisher; Oindrila Bhattacharyya; Allan Tsung; Samilia Obeng-Gyasi
Journal:  J Surg Oncol       Date:  2022-04-22       Impact factor: 2.885

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.